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Abstract Neutrophil elastase is thought to be involved in 
cartilage destruction occurring in rheumatoid arthritis despite 
the local presence of al-proteinase inhibitor. Part of synovial 
fluid al-proteinase inhibitor forms a mixed disulfide with 
immunoglobulin A, which has been postulated to lack inhibitory 
activity. We show here that the immunoglobulin-inhihitor 
complex tightly inhibits neutrophil elastase and catbepsin G, 
bovine pancreatic trypsin and chymotrypsin, and porcine 
pancreatic elastase. Although the rate constant of inhibition of 
neutrophil elastase by immunoglobulin A-bound al-proteinase 
inhibitor (kass = 9.2 × 10 5 M -l" s -I) is about 10-fold lower than 
that measured with the free inhibitor, it is high enough to enable 
efficient inhibition of elastase in vivo. 
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1. Introduction 
Rheumatoid arthritis is a debilitating disease characterized 
by an extensive degradation of  the articular cartilage. Massive 
numbers of neutrophils accumulate in rheumatoid synovial 
fluids where they may release large amounts of NE [1], a 
serine proteinase that cleaves proteoglycans and type II col- 
lagen, the major constituents of articular cartilage [2,3]. NE is 
therefore believed to play a significant pathological role in 
arthritis. 
Synovial fluid contains plasma-derived oqPI, the major 
physiological inhibitor of NE. In rheumatoid arthritis, up to 
30% of synovial fluid CtlPI is bound to IgA via a disulfide link 
between Cys-232, the sole cysteine residue of the inhibitor, 
and Cys-471, the penultimate cysteine residue of the a-chain 
of immunoglobulin [4]. Two lines of evidence suggest that 
binding of oqPI exerts an unfavorable ffect on the evolution 
of rheumatoid arthritis: (i) treatment of patients with D-peni- 
cillamine decreases the concentration of complex and amelio- 
rates their clinical conditions [5,6]; (ii) the concentration of 
complex correlates directly with the development of articular 
erosions in patients with early rheumatoid arthritis [7]. These 
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correlations trongly suggest hat the tzlPI-IgA complex does 
not inhibit NE and significantly lowers the NE inhibitory 
capacity of synovial fluids, thus favoring intra-joint proteoly- 
sis [5,7]. Yet, no attempt has ever been made to check this 
hypothesis. We therefore prepared the complex in vitro and 
tested it on a number of serine proteinases including NE. 
2. Materials and methods 
The source and active site titration of human NE, cathepsin G and 
~aPI, bovine trypsin and chymotrypsin were the same as before [8]. 
Published procedures were used to isolate [9] and titrate [10] porcine 
pancreatic elastase. The p-nitroanilide substrates (Bachem, Switzer- 
land) were dissolved in dimethylformamide whose final concentration 
in the enzymatic reaction medium was 1% (v/v). Fluorescent labelling 
of NE and cqPI was done with celite-bound FITC (Molecular Probes, 
OR) as described by Gennis et al. [11]. The molar ratio of bound 
FITC to 0qPI or NE was deduced from absorbance readings using 
e= 66800 M -1 .cm -1 at 495 nm for protein-bound FITC [12], and 
protein concentration measurements u ing the method of Bradford 
[13]. The degree of labelling ranged from 0.9 to 1.1 for FITC-CtlPI 
and FITC-NE. Human serum IgA (Jackson, PA) was a mixture of 
monomeric (~  90%) and dimeric (~  10%) immunoglobulins. The cal- 
ibration kits used for electrophoresis and gel filtration were from 
Pharmacia (Sweden). 
The immunoassay of ~IPI was done using a double-sandwich ELI- 
SA. The plates were coated with goat anti-human alPI antibodies 
(Nordic, The Netherlands), and the bound cqPI was revealed with 
successive addition of rabbit anti-human alPI antibodies (Behring, 
Germany) and peroxidase-labelled goat anti-rabbit immunoglobulin 
G antibodies (Nordic). 
Electrophoresis and Western blotting were done with a Pharmacia 
Phastsystem apparatus. The samples were incubated with 0.1% SDS 
buffer for 15 min at 25°C and electrophoresed in SDS-polyacrylamide 
gels. After blotting on nitrocellulose, the calibration proteins were 
stained with amido black, while the antigens were revealed by the 
addition of rabbit anti-human alPI (Behring) and anti-human IgA 
a-chain (ICN, CA) antisera, followed by addition of alkaline phos- 
phatase-labelled goat anti-rabbit immunoglobulin G antibodies. 
2.1. Preparation of the oqPl-lgA complex 
cqPI (2 mg/ml) was reacted with 10 mM reduced glutathione 
(Merck, Germany) for 12 h at 4°C in 50 mM HEPES, 100 mM 
NaC1, pH 7.4, in order to free its single cysteinyl groups [14]. The 
excess glutathione was removed by gel filtration through a Sephadex 
G25 column developed with 100 mM Tris-HC1 pH 8.2. The tzlPI- 
containing fractions were concentrated by Centriprep-10 filtration 
(Amicon, MA), and the free thiol of reduced cqPI (eqPI-SH) was 
titrated with DTNB (Sigma, MO) [15], which showed that the inhi- 
bitor was fully reduced. IgA was reacted with 10 mM DTNB for 12 h 
at 4°C in the above pH 7.4 buffer, to facilitate its coupling to cqPI. 
The mixed disulfide (IgA-SS-TNB) was then isolated using a Superose 
6 column (Pharmacia) developed with the above pH 8.2 buffer, and 
concentrated byCentricon-100 filtration (Amicon). 3 mg alPI-SH and 
12 mg IgA-SS-TNB were reacted for 12 h at 4°C in a total volume of 
1.2 ml of the pH 8.2 buffer. 200 p.l portions of this mixture were then 
gel filtrated on a 1 × 30 cm column of Superose 6 eluted with 50 mM 
HEPES buffer pH 7.4 at a flow rate of 25 ml/h. The S1 fractions (Fig. 
1) were pooled and chromatographed on a 0.5×5 cm Mono Q 5/5 
column equilibrated with 50 mM HEPES pH 7.4. Protein elution was 
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done with a linear NaCI gradient at a flow rate of 60 ml/h. The M2 
fractions were pooled, diluted with an equal volume of 50 mM 
HEPES pH 7.4 and concentrated by Centriprep-100 filtration. 
2.2. Enzymatic methods 
All reactions were carried out in 50 mM HEPES, 100 mM NaC1 
buffer pH 7.4 and at 25°C. Titration of proteinases with the (XlPI-IgA 
complex was done as follows. Constant amounts of proteinases were 
reacted with increasing amounts of complex in a total volume of 990 
gl of buffer. After 1 h at 25°C, 10 gl of stock solution of substrate was 
added to measure the residual enzyme activities. The proteinases and 
their final concentrations were: 50 nM NE, 200 nM cathepsin G, 20 
nM bovine chymotrypsin, 200 nM bovine trypsin and 100 nM porcine 
pancreatic elastase. The corresponding substrates and their final con- 
centrations were: 0.1 mM MeOSuc-Ala2-Pro-Val-pNA, 1.5 mM Suc- 
Ala2-Pro-Phe-pNA, 0.2 mM Suc-Ala2-Pro-Phe-pNA, 2 mM Bz-Arg- 
pNA and 0.8 mM Suc-Ala3-pNA. 
The rate of NE inhibition was measured under pseudo-first-order 
conditions, i.e. [I]0 -> 10 [E]0, by reacting 30 nM NE with a mixture of 
(ZlPI-IgA (variable concentration) and 1 mM MeOSuc-Ala2-Pro-Val- 
pNA. The release ofp-nitroaniline was recorded at 410 nm. The pro- 
gress curves were analyzed as described previously [16]. 
3. Results and discussion 
3.1. Preparation of the C~lPI-IgA complex 
(XlPI-SH and IgA-SS-TNB were prepared and mixed as 
described in section 2. Their mixture was then gel filtrated 
on Superose 6, and the eluted proteins were divided into three 
fractions S1, $2 and $3 (Fig. 1A), each of which was electro- 
phoresed, electroblotted and reacted with anti-(xlPI and anti- 
IgA antibodies (Fig. 1B). It can be seen that IgA-bound (xlPI 
is present in S1 whereas free oqPI is present in $2 and $3. 
Fraction S1 was chromatographed on a Mono Q column 
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Fig. 1. A: Superose 6 gel filtration of the cqPI+IgA-SS-TNB reac- 
tion mixture. The arrows indicate the elution volumes of marker 
proteins whose molecular mass are given in kDa. B: Western blot 
analysis of fractions S1 (lanes 3, 4), $2 (lanes 5, 6), and $3 (lanes 7, 
8), and of IgA (lane l) and cqPI (lane 2) controls. The antigens 
were revealed with anti-IgA-c~-chain antibodies (lanes 1, 3, 5, 7) or 
with anti-(x1PI antibodies (lanes 2, 4, 6, 8). 
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Fig. 2. A: Mono Q chromatography of fraction S1 from Fig. 1. B: 
Western blot analysis of fractions M1 (lanes 3, 4), M2 (lanes 5, 6), 
and of IgA (lane 1) and (xlPI (lane 2) controls. The antigens were 
revealed with anti-IgA-c~-chain antibodies (lanes 1, 3, 5) or with 
anti-alPI antibodies (lanes 2, 4, 6). 
which separated the proteins into two major fractions, M1 
and M2 (Fig. 2A), each of which was blotted as in Fig. 1 
(Fig. 2B). M1 contained free IgA whereas M2 contained the 
txiPI-IgA complex. Reaction of 3 mg CtlPI with 12 mg IgA 
yielded about 120 ktg of CtlPI-IgA complex. The adduct was 
pure as judged by electrophoresis on a 7.5% SDS-polyacryl- 
amide gel (not shown). 
This is the first report on the preparation of the complex 
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Fig. 3. Effect of increasing amounts of CtlPI-IgA complex on the ac- 
tivity of constant amounts of NE (O), cat G (e), bovine chymotryp- 
sin (zx), bovine trypsin (• )  and porcine elastase (O). 
C. Adam, J.G. BiethlFEBS Letters 385 (1996) 201-204 203 
"7 
0,I0 
0.05 - 
0.00 
,/// 
0.0 0.4 0.8 1.2 
cqPI-IgA (p.IVI) 
Fig. 5. Effect of the concentration of the (~IPI-IgA complex on k, 
the pseudo-first-order rate constant of NE inhibition at pH 7.4 and 
25°C. The rate constant k was calculated as described in section 2. 
from its individual components. Previous investigators have 
partially purified cqPI-IgA from serum [4,17]. 
3.2. oqPI:IgA stoichiometry and ~ of the complex 
Each a-chain of monomeric IgA has one free cysteine re- 
sidue at its penultimate position. Thus, one molecule of IgA 
may theoretically bind two molecules of (~IPI. We therefore 
investigated the binding stoichiometry of the ~IPI-IgA com- 
plex. The complex migrated as a 220 kDa protein on SDS- 
polyacrylamide g l electrophoresis with immune (Fig. 1A) or 
Coomassie blue staining. It also eluted as a ca. 220 kDa pro- 
tein on calibrated analytical Superose 6 gel filtration (not 
shown), suggesting that it is formed of equimolar amounts 
of (XlPI (Mr = 53 000) and IgA (Mr = 170 000). 
On the other hand, UV absorption spectroscopy gave 
A2S0nm = 13.5, as calculated with a formula published by 1% 
van Iersel et al. [18]. Using the molecular mass of 220 kDa, 
the calculated molar extinction coefficient was e=300000 
M -1 .cm -1 at 280 nm. This value was checked in two ways. 
First the molar concentration of the complex formed with 
FITC-labelled cqPI-IgA complex was determined using 
e=66800 M- l . cm -1 at 495 nm for protein-bound FITC 
[12] and assuming a 1:1 stoichiometry. This molar concentra- 
tion was very close to that determined using e=300000 
M- l . cm -1 at 280 nm. Second, the cqPI-IgA complex was 
reduced with a 10-fold molar excess of dithiothreitol and 
the concentration of free cqPI was measured using an ELISA. 
This result confirmed that obtained with the FITC-(zaPI-IgA 
complex. The E value was used to calculate the concentrations 
of complex solutions used for the enzymatic studies. 
3.3. Inhibitory properties of the oqPI-IgA complex 
Titration of NE, cathepsin G, bovine chymotrypsin, bovine 
trypsin or porcine pancreatic elastase with the (~IPI-IgA com- 
plex yields linear and superimposable titration curves, whose 
intercept with the abscissa indicates that about I mol of (ZlPI- 
IgA inhibits 1 mol of enzyme (Fig. 3). Thus cqPI-IgA behaves 
like an irreversible serine proteinase inhibitor like free cq PI [19]. 
The NE inhibition was investigated in more detail. Free and 
IgA-bound alPI  were reacted with stoichiometric amounts of 
FITC-labelled NE, and the complexes were gel filtrated on 
analytical Superose 6. Fig. 4 shows that the two inhibitory 
complexes elute from the column as 250 kDa and 83 kDa 
proteins. This indicates that the inhibition of NE by oqPI- 
IgA is due to the formation of a ternary NE-alPI- IgA com- 
plex, and not to a NE-induced dissociation of the cqPI-IgA 
complex. When analyzed by SDS-12.5% polyacrylamide gel 
electrophoresis n the presence of ~-mercaptoethanol, the 
NE-cqPI-IgA complex showed bands at 25 kDa and 50 kDa 
corresponding to the light and heavy chains of IgA and one 
band at ca. 80 kDa, also observed upon electrophoresis of the 
NE-(~IPI complex (not shown). The latter band corresponds 
to the classical denaturant-stable irr versible proteinase-inhib- 
itor complex [20]. 
Fig. 5 shows that k, the pseudo-first-order rate constant for 
the inhibition of NE by eqPI-IgA, varies approximately line- 
arly with the inhibitor concentration, indicating that enzyme 
E and inhibitor I associate via a simple bimolecular reaction 
governed by the second-order association rate constant 
k~ 
k~s(E + I----+ EI). As demonstrated previously, 
k - ka~ [Ilo (1) 
1 + [S]o/Km 
where [S]o and Km are the initial substrate concentration and 
the Michaelis constant, respectively [16,21]. Non-linear egres- 
sion analysis of the progress curves yielded k~sl(1 + [S]o/Km), 
from which k~s was calculated using Km= 85 +- 12 gM for the 
NE/MeOSuc-Ala2-Pro-Val-pNA system [16]. In a previous 
investigation we have shown that free (xaPI also inhibits NE 
via a bimolecular reaction characterized by a kass of 
(1.05 + 0.15) X 107 M -1" s -1 [16]. IgA therefore decreases k~s 
by a factor of 11, indicating that the bulky immunoglobulin 
molecule does not dramatically disturb the enzyme-inhibitor 
binding. On the other hand, theory predicts that with a kass of 
ca. 106 M - l ' s  -1, (zlPI-IgA still acts fast enough to prevent 
intra-joint proteolysis [22]. This contradicts the hypothesis 
that (zlPI is inactivated following its binding with IgA [5,7]. 
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Fig. 4. Superose 6 gel filtration of the complexes formed between 
FITC-NE and 0qPI or alPl-IgA complex. The complexes were 
formed by reacting 2 gM FITC-NE with 2.4 p.M inhibitor for 15 
min at pH 7.4 and 25°C. Each complex was chromatographed s pa- 
rately by pouring a 100 Ixl aliquot on a 1 × 30 cm column developed 
with 50 mM HEPES pH 7.4. The arrows indicate the elution of the 
calibration proteins. 
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